



For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice – New Programs:** Combined LHRH Agonist and Aromatase Inhibitor for Breast Cancer
- **Highlights of Changes in Protocols, PPPOs and Patient Handouts –** Fluoropyrimidine-Based Gastrointestinal Protocols, Breast Protocols for Male Patients
- **Cancer Drug Manual – Revised:** Anastrozole, Exemestane, Letrozole, Interferon, Melphalan, Methotrexate
- **Benefit Drug List –** Anastrozole, Buserelin, Exemestane, Goserelin, Letrozole, Leuprolide
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts – New:** UBRAJLHRHA, BRAVLHRHA, Revised: BRAVABR, UCNBEV, GIAJCAP, GIAVCP, GIAVPG, GIFUIP, GIHIPEC, GIRCAP, GIRCRT, HNNAVP Gender Deleted from Eligibility in Breast Protocols: BRAJACTG, BRAJCEFG, BRAJFEC, BRINFCEG, BRINFCEFG, UBRLA2, BRLAACD, UBRLACEF, BRLACEFG, BRLATACG Various Changes in Fluoropyrimidine-Based Gastrointestinal Protocols: GIAJCAPOX, GIAJFFOX, GIAJFL, GIAVFL, GIAVTZCAP, GICAPIRI, GICAPOX, GICART, GICIRB, UGICOXB, GICPART, GIEFUPRT, GIFFIRB, UGIFFOXB, UGIFIRINOX, GIFOLFIRI, GIFOLFOX, GIFUART, GIFUC, GIFUFA, GIFUIP, GIFUPART, GIGAIRT, GIGAJCC, GIGAJCPRT, GIGAVCC, GIGAVCCT, GIGAVCFT, GIGAVECC, GIGAVECF, GIGECC, GIGECF, GIGFOLFIRI, GIHIPEC, GIRAJCOX, GIRAJFFOX, GIRINFRT
- **Website Resources and Contact Information**

EDITOR'S CHOICE

NEW PROGRAMS

The Provincial Systemic Therapy Program has approved the following program effective 1 June 2015:

Combined LHRH Agonist and Aromatase Inhibitors for Breast Cancer (UBRAJLHRHA, BRAVLHRHA) – Tamoxifen is the standard endocrine therapy for premenopausal women with hormone receptor positive breast cancer. These new combinations offer an option to those patients who cannot be treated with tamoxifen (e.g., due to thromboembolic disease) or have tamoxifen intolerance.

HIGHLIGHTS OF CHANGES IN PROTOCOLS, PPPOs AND PATIENT HANDOUTS

Fluoropyrimidine-Based Gastrointestinal Chemotherapy Regimens – Several changes have been implemented:

1. Protocols have been revised to clarify INR monitoring, warfarin interactions, and potential cardiac toxicity.
2. PPPOs have been updated to ensure INR monitoring and option of weekly nursing assessment are

HIGHLIGHTS OF CHANGES IN PROTOCOLS, PPPOs AND PATIENT HANDOUTS

consistently included in all orders.

3. Patient handouts have been expanded to include loperamide dosing for self-management of diarrhea.

Breast Chemotherapy Protocols – The eligibility of several protocols have been clarified to indicate that the use of these regimens is not restricted to female patients only.

CANCER DRUG MANUAL

HIGHLIGHTS OF REVISED MONOGRAPHS AND HANDOUTS

Aromatase Inhibitors: Blood clots as a side effect has been deleted from the patient handouts for anastrozole, exemestane and letrozole. Although venous thromboembolic events have been reported with aromatase inhibitors in the pivotal trials, the increased risk of blood clot is considered to be low with the additional knowledge gained through clinical experience since the time of the trials. Given that these agents are standard options for patients who cannot take tamoxifen due to thromboembolic risks, the caution on blood clot has been deleted after consultation with the BCCA Breast Tumour Group.

Other changes

- **Interferon:** supplier information updated
- **Melphalan:** direct IV administration information clarified, supplier information updated
- **Methotrexate:** dosing range for high dose regimens clarified

BENEFIT DRUG LIST

NEW PROGRAMS

The following programs have been added to the [Benefit Drug List](#) effective 1 June 2015:

Protocol Title	Protocol Code	Benefit Status
Adjuvant therapy for breast cancer using a LHRH agonist (buserelin, goserelin, leuprolide) and an aromatase inhibitor (anastrozole, exemestane, letrozole)	UBRAJLHRHA	Restricted
Therapy for advanced breast cancer using a LHRH agonist (buserelin, goserelin, leuprolide) and an aromatase inhibitor (anastrozole, exemestane, letrozole)	BRAVLHRHA	Class I

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring BCCA Compassionate Access Program approval are prefixed with the letter “U”.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):				
CODE	Protocol	PPPO	Patient Handout	Protocol Title
UBRAJLHRHA	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Adjuvant Therapy for Breast Cancer Using a LHRH Agonist and an Aromatase Inhibitor
BRAVLHRHA	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Therapy for Advanced Breast Cancer Using a LHRH Agonist and an Aromatase Inhibitor

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):					
CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAVABR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Type of infusion bag and equipment clarified</i>	Palliative Therapy for Metastatic Breast Cancer using PACLitaxel-NAB
UCNBEV	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Bevacizumab treatment schedule clarified</i>	Palliative Therapy for Recurrent Malignant Gliomas Using Bevacizumab With or Without Concurrent Etoposide or Lomustine
GIAJCAP	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Side effects sections expanded</i>	Adjuvant Therapy of Colon Cancer Using Capecitabine
GIAVCAP	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Side effects sections expanded</i>	Palliative Therapy of Advanced Colorectal Cancer using Capecitabine
GIAVPG	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Dose modification clarified</i>	First-line Palliative Chemotherapy for Advanced Gallbladder Cancer and Cholangiocarcinoma using Gemcitabine and Cisplatin
GIFUIP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Precautions on myocardial ischemia and DPD deficiency, maximum mitomycin dose added</i>	Chemotherapy of Pseudomyxoma Peritonei Using Intraperitoneal Mitomycin and Fluorouracil
GIHIPEC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Precautions on myocardial ischemia and maximum mitomycin dose added</i>	Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Limited Advanced Colorectal and Appendiceal Carcinomas Using Oxaliplatin and Fluorouracil
GIRCAP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Eligibility clarified in protocol, side effects sections expanded in patient handout</i>	Adjuvant Therapy for Stage II and III Rectal Cancer Previously Treated with Preoperative Radiation Therapy Using Capecitabine
GIRCRT	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Side effects sections expanded</i>	Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma Using Capecitabine and Radiation Therapy

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
HNNAVP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Minor typo corrected in Dose Modifications	Palliative Chemotherapy for Advanced Head and Neck Nasopharyngeal Carcinoma with Weekly CISplatin

The eligibility of these breast protocols has been revised so they are not restricted to female patients:

CODE	Protocol Title
BRAJACTG	Adjuvant Therapy for Breast Cancer Using Dose Dense Therapy: DOXOrubicin and Cyclophosphamide Followed by PACLitaxel
BRAJCEFG	Adjuvant Therapy for Breast Cancer Using Cyclophosphamide, Epirubicin, Fluorouracil and Filgrastim
BRAJFEC	Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide
BRINCFEF	Therapy for Inflammatory Breast Cancer Using Cyclophosphamide, Epirubicin and Fluorouracil
BRINCFEFG	Therapy for Inflammatory Breast Cancer Using Cyclophosphamide, Epirubicin, Fluorouracil and Filgrastim
UBRLA2	Therapy for Locally Advanced breast cancer Using Cyclophosphamide, DOXOrubicin and Fluorouracil
BRLAACD	Treatment of Locally Advanced Breast Cancer Using DOXOrubicin and Cyclophosphamide Followed by DOCetaxel
UBRLACEF	Therapy for Locally Advanced Breast Cancer using Cyclophosphamide, Epirubicin and Fluorouracil
BRLACEFG	Therapy for Locally Advanced Breast Cancer Using Cyclophosphamide, Epirubicin, Fluorouracil and Filgrastim
BRLATACG	NEOAdjuvant Therapy for Breast Cancer Using Dose Dense Therapy: PACLitaxel Followed by DOXOrubicin and Cyclophosphamide

The followings have been revised regarding INR monitoring, warfarin interaction, cardiac toxicity, nursing assessment, and loperamide dosing.

CODE	Protocol	PPPO	Patient Handout	Protocol Title
GIAJCAPOX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer Using Oxaliplatin and Capecitabine
GIAJFFOX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer Using Oxaliplatin, Fluorouracil and Leucovorin
GIAJFL	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Adjuvant Therapy of Colon Cancer Using Fluorouracil Injection and Infusion and Leucovorin Infusion
GIAVFL	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Fluorouracil Injection and Infusion and Leucovorin Infusion
GIAVTZCAP	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Therapy of Metastatic Neuroendocrine Cancer Using Temozolomide and Capecitabine
GICAPIRI	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan and Capecitabine in Patients Unsuitable for GIFOLFIRI
GICAPOX	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin and Capecitabine
GICART	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy
GICIRB	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Bevacizumab and Capecitabine
UGICOXB	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Bevacizumab and Capecitabine
GICPART	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Combined Modality Therapy for Carcinoma of the Anal Canal Using CISplatin, Capecitabine and Radiation Therapy

CODE	Protocol	PPPO	Patient Handout	Protocol Title
GIEFUPRT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Combined Modality Therapy for Locally Advanced esophageal Cancer Using Fluorouracil and CISplatin
GIFFIRB	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil, Leucovorin, and Bevacizumab
UGIFFOXB	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Fluorouracil, Leucovorin and Bevacizumab
UGIFIRINOX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Combination Chemotherapy for Advanced Pancreatic Adenocarcinoma Using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin
GIFOLFIRI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil and Leucovorin
GIFOLFOX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Fluorouracil and Leucovorin
GIFUART	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Combined Modality Curative Therapy for Carcinoma of the Anal Canal Using Mitomycin, Fluorouracil and Radiation Therapy
GIFUC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Chemotherapy for Upper Gastrointestinal Tract Cancer and Metastatic Anal Cancer Using Infusional Fluorouracil and CISplatin
GIFUFA	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Therapy for Advanced Colorectal Cancer Using Leucovorin and Fluorouracil
GIFUIP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chemotherapy of Pseudomyxoma Peritonei Using Intraperitoneal Mitomycin and Fluorouracil
GIFUPART	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Combined Modality Curative Therapy for Carcinoma of the Anal Canal Using CISplatin, Infusional Fluorouracil and Radiation Therapy
GIGAIRT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Combined Modality Adjuvant Therapy for Completely Resected Gastric Adenocarcinoma Using Fluorouracil and Folinic Acid and Radiation Therapy
GIGAJCC	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Adjuvant Chemotherapy of Gastric Cancer Patients with D2 Resection or Ineligible for Adjuvant Chemoradiation, Using CISplatin and Capecitabine
GIGAJCPRT	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Adjuvant Chemotherapy of Gastric Cancer Patients with Completely Resected Gastric Cancer Using CISplatin and Capecitabine and Radiation Therapy
GIGAVCC	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Therapy for Metastatic or Locally Advanced Gastric Cancer Using CISplatin and Capecitabine
GIGAVCCT	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Adjuvant Chemotherapy of Gastric Cancer Patients with Completely Resected Gastric Cancer Using CISplatin and Capecitabine and Radiation Therapy
GIGAVCFT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma using CISplatin, Infusional Fluorouracil and Trastuzumab
GIGAVECC	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Therapy for Metastatic or Locally Advanced Gastric or Esophagogastric Cancer Using Epirubicin, CISplatin and Capecitabine
GIGAVECF	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Therapy for Metastatic or Locally Advanced Gastric, Esophagogastric Cancer Using Epirubicin, CISplatin and Infusional Fluorouracil
GIGECC	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus Using Epirubicin, CISplatin and Capecitabine
GIGEFC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus using Epirubicin, CISplatin and Infusional Fluorouracil
GIGFOLFIRI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Second Line Palliative Combination Chemotherapy for Metastatic Gastric or Esophageal Adenocarcinoma Using Irinotecan, Fluorouracil and Leucovorin
HIPEC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Limited Advanced Colorectal and Appendiceal Carcinomas Using Oxaliplatin and Fluorouracil
GIRAJCOX	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Adjuvant Combination Chemotherapy for Stage III Rectal Cancer Using Oxaliplatin and Capecitabine
GIRAJFFOX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Adjuvant Combination Chemotherapy for Stage III Rectal Cancer Using Oxaliplatin, Fluorouracil and Leucovorin

CODE	Protocol	PPPO	Patient Handout	Protocol Title
GIRINFRT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma Using Capecitabine, Infusional Fluorouracil and Radiation Therapy

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	www.bccancer.bc.ca
Systemic Therapy Update	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy/systemic-therapy-update
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
Cancer Drug Manual	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual
Cancer Management Guidelines	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
CON Pharmacy Educators	www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor			bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update the contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604.877.6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604.877.6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604.675.8003 Toll Free 888.675.8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	604.877.6000 x 672247		mclin@bccancer.bc.ca
Nursing Professional Practice	604.877.6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888.355.0355	604.708.2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604.877.6277	604.708.2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250.712.3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604.851.4710 Toll Free 877.547.3777		
BCCA-Centre for the North	250.645.7300 Toll Free 888.775.7300		
BCCA-Fraser Valley Centre	604.930.2098 Toll Free 800.523.2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250.712.3900 Toll Free 888.563.7773		
BCCA-Vancouver Centre	604.877.6000 Toll Free 800.663.3333		
BCCA-Vancouver Island Centre	250.519.5500 Toll Free 800.670.3322		

EDITORIAL REVIEW BOARD

Mário de Lemos, PharmD, MSc (Oncol) (Acting Editor)
 Victoria Kletas, MSc (Clin Pharm)
 Caroline Lohrisch, MD
 Robert Crisp, BScPT, MBA

Beth Morrison, MLS
 Ava Hatcher, RN
 Rob Watt, BSc (Pharm)